Home・Aktien・CytoSorbents Corp

CytoSorbents Corp

Geschlossen

BrancheGesundheitswesen

0.37 19.35

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.36

Max

0.37

Schlüsselkennzahlen
By Trading Economics
Einkommen	-4.4M -9.5M
Verkäufe	769K 9.6M
EPS	-0.07
Gewinnspanne	-99.107
Angestellte	129
EBITDA	547K -3.3M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+102.7% upside

Dividenden
By Acuity
Nächstes Ergebnis	12. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	572K 24M
Vorheriger Eröffnungskurs	-18.98
Vorheriger Schlusskurs	0.37

Nachrichtenstimmung

By Acuity

50%

147 / 340 Ranking in Healthcare

CytoSorbents Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 20:01 UTC

Cytosorbents Corp shares are higher today, continuing a strong upward trend since Thursday's close amid positive market sentiment and related equity gains.

20. Aug. 2026, 23:01 UTC

Cytosorbents Corp shares are lower in after-market hours, continuing a decline amid broader market pressure from disappointing sales growth at Walmart Inc.

18. Aug. 2026, 20:06 UTC

Cytosorbents Corp shares are lower today, continuing a downward trend amid rising U.S. Treasury yields and persistent inflation concerns. No specific news was identified.

17. Aug. 2026, 19:36 UTC

Cytosorbents Corp shares are lower today amid rising Treasury yields and inflation concerns. The stock remains above its 20-day moving average.

14. Aug. 2026, 20:06 UTC

Cytosorbents Corp shares are higher today, continuing a notable upward trend despite mixed market sentiment and no specific company news identified.

13. Aug. 2026, 19:16 UTC

Cytosorbents Corp shares are higher today, reflecting routine performance and buoyed by overall market sentiment, despite no specific news driving the movement.

12. Aug. 2026, 19:46 UTC

Cytosorbents Corp is trading higher, building on gains since Tuesday's close. Broader market sentiment is positive amid favorable inflation data and strong tech earnings.

11. Aug. 2026, 22:01 UTC

Cytosorbents Corp shares are higher in after-market trading, following notable activity after the market closed, despite no specific company news identified.

10. Aug. 2026, 19:21 UTC

News

Cytosorbents Corp shares are higher, driven by gains in the Health Care Equipment sector. The company reported Q2 revenue of $9.63 million, exceeding forecasts.

7. Aug. 2026, 20:51 UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6. Aug. 2026, 19:16 UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5. Aug. 2026, 22:06 UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4. Aug. 2026, 21:01 UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3. Aug. 2026, 19:56 UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31. Juli 2026, 20:06 UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29. Juli 2026, 20:08 UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28. Juli 2026, 18:46 UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

27. Juli 2026, 18:41 UTC

Cytosorbents Corp shares are lower today amid notable volatility, with no specific news identified to explain the decline during Monday's session.

24. Juli 2026, 19:06 UTC

Cytosorbents Corp shares are lower, marking three consecutive daily declines amid a broader market pullback influenced by falling crude oil prices.

22. Juli 2026, 20:13 UTC

Cytosorbents Corp shares are lower in after-market hours amid rising crude oil prices and escalating U.S.-Iran tensions. The stock remains below its 20-day moving average.

21. Juli 2026, 18:31 UTC

Cytosorbents Corp shares are higher today, reflecting broader market optimism despite earlier fluctuations. Strong buying in technology stocks supports this upward movement.

20. Juli 2026, 19:16 UTC

News

Cytosorbents plans to report second-quarter 2026 results on August 6. The company is also pursuing FDA and Health Canada approval for its DrugSorb®-ATR device.

Peer-Vergleich

Kursveränderung

CytoSorbents Corp Prognose

Kursziel

By TipRanks

102.7% Vorteil

12-Monats-Prognose

Durchschnitt 0.75 USD 102.7%

Hoch 0.75 USD

Tief 0.75 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CytoSorbents Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für CytoSorbents Corp – Dist abgegeben haben.

Stimmung

By Acuity

147 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.